Brookfield Infrastructure Corporation (BIPC) Chart

Element 25 managing director Justin Brown talked with Proactive about the recent completion of the Tokyo Bay HPMSM Facility Scoping Study in partnership with Nissin Chemical Corporation. The company said the results of the scoping study were positive enough to justify advancing the project to the pre-feasibility stage. Brown explained that the Tokyo Bay site offers unique advantages, including a co-located sulfuric acid plant, deepwater port access, and supporting infrastructure critical for high-purity manganese sulfate production. “We took our learnings from the detailed work we’ve done in Louisiana… and converted them to a Japanese setting,” Brown said. He also noted that Japan's regulatory and geopolitical environment makes it an ideal location for refining and supplying the local battery market. Looking ahead, Brown confirmed that Element 25 and Nissin Chemical will conduct deeper engineering and cost analysis under their existing MOU, with a final investment decision targeted for June 2026. The next milestone will be the pre-feasibility study, expected later this year. Brown also discussed how the Tokyo Bay project fits into the company’s broader “design one, build many” strategy, which aims to establish a global network of refineries fed by ethically sourced manganese from Element 25’s Butcherbird mine. In addition to activity in Japan, Brown highlighted ongoing work in Europe and updates on the Butcherbird expansion and Louisiana project, with construction planned to commence later this year. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications so you never miss an update. #Element25 #Manganese #BatteryMetals #TokyoBay #CriticalMinerals #EVSupplyChain #HPMSM #ButcherbirdProject #CleanEnergyMaterials #JapanRefinery #MiningNews #GreenMetals #ProactiveInvestors

Ananda Pharma Plc finance director Jeremy Sturgess-Smith talked with Proactive's Stephen Gunnion about the appointment of Chris Tovey as a strategic advisor. Tovey brings significant experience from his time as chief operating officer at GW Pharmaceuticals and later Jazz Pharmaceuticals. According to Sturgess-Smith: “He’s going to bring all that experience to Ananda,” helping guide the company through its regulatory path and corporate development. Sturgess-Smith also touched on Ananda securing ethics approval to begin its first human trial of MRX1, a key milestone for the company’s therapeutic pipeline. He noted this was the first ethics approval of its kind for any Ananda trial, with recruitment expected to begin shortly in Australia. “It’s very, very exciting to have that ethics approval in the bag,” he said. Looking ahead, the company also expects ethics approvals for studies into chemotherapy-induced peripheral neuropathy and endometriosis in the next six months. For more interviews and updates, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and hit the notification bell to stay informed.** #AnandaPharma #MRX1Trial #ClinicalTrials #CannabinoidMedicine #BiotechNews #PharmaceuticalInnovation #EthicsApproval #GWPharma #DrugDevelopment #Epidiolex #HealthInnovation #ProactiveInvestors

Tonix Pharmaceuticals is making waves in the healthcare industry with the launch of TONIX ONE™ a fully integrated digital platform designed to empower migraine patients with better tools for understanding and managing their condition. In an exclusive discussion with Proactive’s Steve Darling, Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, unveiled the platform’s innovative features and strategic partnerships aimed at transforming migraine care. By collaborating with UpScript Telemedicine, ProModRx, Blink Health, and a leading mobile application specializing in disease tracking, symptom reporting, and management, TONIX ONE offers a comprehensive, patient-centric solution. Dr. Lederman highlighted that TONIX ONE™ beyond conventional migraine education by providing critical insights into the limitations of oral medications, which can sometimes result in delayed or ineffective symptom relief. The platform bridges the gap between patients and healthcare providers, offering direct access to migraine specialists via telehealth consultations and seamless e-prescription requests—ensuring a faster, more effective pathway to treatment. With this initiative, Tonix Pharmaceuticals aims to not only educate and empower patients in their treatment journey but also eliminate the barriers to care that many migraine sufferers face. By integrating advanced digital health solutions,TONIX ONE™ stands at the forefront of a new era in migraine management, offering patients greater control over their health and well-being. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MigraineTreatment #TonixOne #DigitalHealth #Telemedicine #ZembraceSymTouch #Tosymra #HealthcareInnovation #PharmaNews #ProactiveInvestors

4GLOBAL PLC (AIM:4GBL) CEO Eloy Mazon talked with Proactive's Stephen Gunnion about the company’s expanded agreement with Sport England. The updated contract deepens 4GLOBAL’s role in delivering data-led insights to support increased sports participation across England, extending beyond facilities to include outdoor and informal activity spaces. Mazon explained that this new phase builds on a successful four-year partnership which helped boost participation by over 30%. “We like to think we play a very significant part in achieving those outcomes,” he said, referring to the impact of 4GLOBAL’s data platform on investment decisions in grassroots sports. Now, Sport England is shifting focus to track physical activity beyond formal facilities, such as cycling paths and running tracks. 4GLOBAL’s recently launched insight platform plays a key role by integrating multiple datasets to generate predictive insights. Mazon said, “This contract…places us at the centre of sport and physical activity in England.” He added that the broader ecosystem engagement—covering everything from local authorities to gym operators—offers not only data value for Sport England but commercial opportunities for 4GLOBAL. Mazon also highlighted the strategic value of this multi-year, multi-million-pound contract as part of the company’s move toward recurring revenue and EBITDA growth. “The focus for us going forward is to really grow EBITDA, because that provides us with that free cash flow…to invest in growth,” he noted. For more CEO interviews and market updates, head to Proactive's YouTube channel. Don’t forget to like this video, subscribe to the channel, and turn on notifications for the latest updates. #4GLOBAL #SportEngland #DataAnalytics #PhysicalActivity #GrassrootsSports #SportsInvestment #ARRGrowth #EBITDA #SmartData #ProactiveInvestors #UKSport